Early diagnosis of pancreatic cancer: challenges and new developments.
Early diagnosis of pancreatic cancer: challenges and new developments.
复制标题
DOI：
10.2217/bmm.12.69
复制
发表时间：
2012-10
影响因子：
2.2
通讯作者：
Batra SK
中科院分区：
文献类型：
--
作者：
Kaur S;Baine MJ;Jain M;Sasson AR;Batra SK
胰腺癌是一种致命的恶性肿瘤，其发病率几乎相当于死亡率。复杂的病理生理学、早期诊断和预后标志物的缺乏以及对放射和化学疗法的无反应性是成功治疗的主要障碍。即使在侵入性病例的初始阶段，治疗剂的性能也很差，这强调了早期检测对提高生存率的重要性。本综述讨论了生物标志物的挑战和进展，包括血清学特征，循环肿瘤细胞，自身抗体，表观遗传标志物和miRNA，正在探索在早期阶段检测这种癌症。考虑到恶性病变的发展与完全爆发的原发性和转移性胰腺癌之间的长时间间隔，正在考虑开发潜在的诊断和预后标志物的独特机会。
Pancreatic cancer is a lethal malignancy with its incidence almost equivalent to mortality. The complex pathophysiology, absence of early diagnostic and prognostic markers and unresponsiveness to radiation and chemotherapies are major barriers against successful therapy. Poor performance of therapeutic agents, even in the initial stage of invasive cases, emphasizes the importance of early detection for improved survival. The present review discusses the challenges and advances in biomarkers including serological signatures, circulating tumor cells, autoantibodies, epigenetic markers and miRNAs that are being explored to detect this cancer at early stages. Considering the long time gap between the development of malignant lesions and full-blown primary and metastatic pancreatic cancer, unique opportunities are being contemplated for the development of potential diagnostic and prognostic markers.